Lymphir
Denileukin diftitox-cxdl · Citius Pharmaceuticals, Inc.
CANCER MEDICINE · PRESCRIPTION ONLY (USA)Lymphir ingredients
| Active ingredient | Strength |
|---|---|
| Denileukin Diftitox | 300 ug/2mL |
What Lymphir is used for
Lymphir is a cancer medicine (cd25-directed cytotoxin). Its approved uses are listed on the official FDA label below.
Key facts
- Brand
- Lymphir
- Generic name
- Denileukin diftitox-cxdl
- Made by
- Citius Pharmaceuticals, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- CD25-directed Cytotoxin
- FDA approval
- Biologic licence (BLA) BLA761312
- On the US market since
- 2025
Official information
- Lymphir prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Denileukin diftitox-cxdl)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lymphir?
Lymphir (Denileukin diftitox-cxdl) is a cancer medicine made by Citius Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Lymphir?
Lymphir contains Denileukin Diftitox (300 ug/2mL).
From the FDA National Drug Code directory (open.fda.gov, public domain). Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA